Hormone replacement (estradiol) — The Systemic Geroprotector for Women
Estradiol is the primary female sex hormone, playing a critical role in maintaining cardiovascular, bone, and cognitive health. The age-related decline of estradiol during menopause accelerates biological aging in women, and timely hormone replacement therapy (HRT) has been shown to mitigate these effects and reduce all-cause mortality when initiated early in the postmenopausal period.
Mechanism of Action
Estradiol exerts its effects primarily through estrogen receptors (ERα and ERβ), which act as ligand-activated transcription factors regulating the expression of hundreds of genes involved in cellular metabolism, antioxidant defense, and inflammation. Activation of ERs enhances mitochondrial function, upregulates antioxidant enzymes via MAPK and NF-κB signaling pathways, and improves insulin sensitivity. In preclinical models, 17α-estradiol (a non-feminizing stereoisomer) has been shown to extend lifespan in male mice by improving metabolic parameters and reducing hypothalamic inflammation, though standard HRT in humans utilizes 17β-estradiol.
Human Trial Evidence
Large observational studies, including data from the UK Biobank and the Women's Health Initiative, indicate that early initiation of hormone replacement therapy (HRT) near the onset of menopause is associated with reduced all-cause mortality, improved cardiovascular outcomes, and preservation of bone density. The ELITE trial demonstrated that estradiol therapy initiated early in postmenopause significantly slowed the progression of subclinical atherosclerosis compared to late initiation. However, HRT is not currently approved specifically for lifespan extension.
Dosing Protocol
Typical systemic dosing for menopausal hormone therapy ranges from 0.5 to 2.0 mg/day for oral estradiol, or 0.025 to 0.1 mg/day for transdermal patches. Transdermal routes are often preferred to avoid first-pass hepatic metabolism and reduce thrombotic risk. Progesterone must be co-administered in women with an intact uterus to prevent endometrial hyperplasia. Prescription required.
Safety & Contraindications
Systemic estrogen therapy carries risks of venous thromboembolism, stroke, and certain hormone-sensitive cancers (e.g., breast and endometrial cancer), particularly with oral administration or prolonged use. It is contraindicated in individuals with a history of estrogen-dependent neoplasia, undiagnosed abnormal genital bleeding, active liver disease, or a history of deep vein thrombosis. Prescription required.